title: Thermonema lapsum gen. nov., sp. nov., a Thermophilic Gliding Bacterium

authors: Hudson, J. Andrew

subjects: biology

abstract: We previously reported the isolation of five strains of a thermophilic gliding organism. These strains are described here as a new genus and species, Thermonema lapsum. The isolates can be readily distinguished from other thermophilic gliding bacteria as they are apparently unicellular aerobic filaments that grow optimally at 60°C. Their cell walls are similar in ultrastructure to those of gram-negative cells, but they are susceptible to penicillin G. Our isolates can be grown on a fully defined medium containing amino acids. Oxidation-versus-fermentation tests indicate that deamination takes place. The type strain, strain 23/9, has been deposited with the American Type Culture Collection as strain ATCC 43542.

text: Thermonema lapsum gen. nov., sp. nov., a Thermophilic Gliding Bacterium We previously reported the isolation of five strains of a thermophilic gliding organism. These strains are described here as a new genus and species, Thermonema lapsum. The isolates can be readily distinguished from other thermophilic gliding bacteria as they are apparently unicellular aerobic filaments that grow optimally at 60°C. Their cell walls are similar in ultrastructure to those of gram-negative cells, but they are susceptible to penicillin G. Our isolates can be grown on a fully defined medium containing amino acids. Oxidation-versus-fermentation tests indicate that deamination takes place. The type strain, strain 23/9, has been deposited with the American Type Culture Collection as strain ATCC 43542.

year: 1989

title: Modelling and testing of long range battery electric vehicle performance

authors: Duke, Mike

subjects: battery electric vehicles

abstract: There are two significant issues facing road transport in the medium to long term: the depletion of cheap oil reserves and the need to reduce carbon emissions. A long term solution for passenger cars could be the introduction of battery electric vehicles (BEVs). However, one of the main problems associated with the current generation of BEVs is their short range relative to conventional internal combustion engine (ICE) cars. 
To investigate this issue, a long range battery electric vehicle, the UltraCommuter (UC), was constructed by the University of Waikato in partnership with HybridAuto Ltd. This paper describes the development, modelling and testing of the UC and its performance in the 2007 World Solar Challenge.

text: Modelling and testing of long range battery electric vehicle performance There are two significant issues facing road transport in the medium to long term: the depletion of cheap oil reserves and the need to reduce carbon emissions. A long term solution for passenger cars could be the introduction of battery electric vehicles (BEVs). However, one of the main problems associated with the current generation of BEVs is their short range relative to conventional internal combustion engine (ICE) cars. 
To investigate this issue, a long range battery electric vehicle, the UltraCommuter (UC), was constructed by the University of Waikato in partnership with HybridAuto Ltd. This paper describes the development, modelling and testing of the UC and its performance in the 2007 World Solar Challenge.

year: 2008

title: Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database

authors: Lawrenson, Ross

abstract: Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. 
Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. 
Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen.
Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.

text: Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. 
Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. 
Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen.
Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.

year: 2023-02-10